Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 14/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 13/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | THRB | P10828 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7228294 | 0.93 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 | |
| SCHEMBL7221366 | 0.92 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 | |
| SCHEMBL7219818 | 0.92 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 | |
| SCHEMBL7223165 | 0.92 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 | |
| SCHEMBL7220488 | 0.91 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 | |
| SCHEMBL7223187 | 0.90 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 | |
| SCHEMBL7222372 | 0.90 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 | |
| SCHEMBL7228603 | 0.90 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 | |
| SCHEMBL7228609 | 0.90 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 | |
| SCHEMBL7220779 | 0.90 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| WO-2024168320-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DEMENTIA | ANAND RENE (US) | 2024-08-15 | — | — | WO | claimed |
| US-20240219394-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-07-04 | — | — | US | claimed |
| EP-4382612-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-06-12 | — | — | EP | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| WO-2023013791-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | 味の素株式会社 | 2023-02-09 | — | — | WO | claimed |
| US-20220257603-A1 | COMBINATION THERAPY FOR TREATING MTAP-DEFICIENT TUMORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-18 | — | — | US | claimed |
| US-20150297623-A1 | METHODS FOR TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-22 | — | — | US | claimed |
| US-20140271606-A1 | METHODS OF USING ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING BLEEDING DISORDERS | BAYER HEALTHCARE LLC | 2014-09-18 | — | — | US | claimed |
| WO-2014074529-A1 | METHODS FOR TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-15 | — | — | WO | claimed |
| WO-2004070000-A2 | HTLV-I-CELL BINDING AND INHIBITION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-08-19 | — | — | WO | claimed |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | HALOZYME HYPERCON, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12558323-B2 | Particle formation and morphology | ELEKTROFI, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | ELEKTROFI INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260000616-A1 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | ELEKTROFI INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20090208550-A1 | Methods and compositions for treating hepatic diseases | NEW YORK UNIVERSITY | 2009-08-20 | — | — | US | disclosed |
| WO-2009055021-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATIC DISEASES | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008131922-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | WO | disclosed |
| WO-2004070000-A2 | HTLV-I-CELL BINDING AND INHIBITION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-08-19 | — | — | WO | disclosed |
| US-6545002-B1 | Treating asthma, diarrhea, insulin resistance, diabetes, ischemia/reprefusion injuries, diabetic retinopathy or hyperbaric oxygen-induced retinopathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000616-A1 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | ALB, TNF, TTR | ADORA2B 4301/4885ADORA2A 3439/4885ADORA1 4507/4885 |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | ALB, S100P, S100A8 | ADORA2B 3145/4885ADORA2A 2833/4885ADORA1 2871/4885 |
| US-12558323-B2 | Particle formation and morphology | CD63, EXOSC10, EPCAM | ADORA2B 4009/4885ADORA2A 3001/4885ADORA1 3176/4885 |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | FLNB, FLNA, FUS | ADORA2B 1022/4885ADORA2A 3104/4885ADORA1 2292/4885 |
| US-20150297623-A1 | METHODS FOR TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS | P2RY1, P2RX3, P2RY4 | ADORA2B 16/4885ADORA2A 8/4885ADORA1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.